Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study led by University of Oxford researchers on over 82,000 participants has shown that difficulty hearing spoken conversations is associated with up to 91% increased risk of dementia.

Elderly woman with hearing aid on grey background. Close up.

Hearing impairment affects around 1.5 billion individuals worldwide (World Health Organization), and there is growing evidence that this could increase the risk of dementia. A major component of hearing impairment is difficulty hearing speech in noisy environments (speech-in-noise hearing impairment). This can have a large impact on the day-to-day functioning of affected individuals who can struggle to follow conversations or hear announcements in noisy environments. However, until now it was unclear whether difficulty hearing speech-in-noise was associated with developing dementia.

This has now been robustly investigated in a new study led by the University of Oxford’s Nuffield Department of Population Health (NDPH) published today in Alzheimer's & Dementia: The Journal of the Alzheimer's Association. The study involved over 82,000 women and men aged 60 years or older from UK Biobank. At the beginning of the study, participants were asked to identify spoken numbers against a background of white noise and based on this test were grouped by the researchers into normal, insufficient and poor speech-in-noise hearing.

Read the full story on the University of Oxford website.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.